BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 20832752)

  • 1. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma.
    Mir SE; De Witt Hamer PC; Krawczyk PM; Balaj L; Claes A; Niers JM; Van Tilborg AA; Zwinderman AH; Geerts D; Kaspers GJ; Peter Vandertop W; Cloos J; Tannous BA; Wesseling P; Aten JA; Noske DP; Van Noorden CJ; Würdinger T
    Cancer Cell; 2010 Sep; 18(3):244-57. PubMed ID: 20832752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WEE1 inhibition sensitizes osteosarcoma to radiotherapy.
    PosthumaDeBoer J; Würdinger T; Graat HC; van Beusechem VW; Helder MN; van Royen BJ; Kaspers GJ
    BMC Cancer; 2011 Apr; 11():156. PubMed ID: 21529352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe.
    De Witt Hamer PC; Mir SE; Noske D; Van Noorden CJ; Würdinger T
    Clin Cancer Res; 2011 Jul; 17(13):4200-7. PubMed ID: 21562035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokinetic effects of Wee1 disruption in pancreatic cancer.
    Chang Q; Chandrashekhar M; Ketela T; Fedyshyn Y; Moffat J; Hedley D
    Cell Cycle; 2016; 15(4):593-604. PubMed ID: 26890070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.
    Hirai H; Iwasawa Y; Okada M; Arai T; Nishibata T; Kobayashi M; Kimura T; Kaneko N; Ohtani J; Yamanaka K; Itadani H; Takahashi-Suzuki I; Fukasawa K; Oki H; Nambu T; Jiang J; Sakai T; Arakawa H; Sakamoto T; Sagara T; Yoshizumi T; Mizuarai S; Kotani H
    Mol Cancer Ther; 2009 Nov; 8(11):2992-3000. PubMed ID: 19887545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma.
    Harris PS; Venkataraman S; Alimova I; Birks DK; Balakrishnan I; Cristiano B; Donson AM; Dubuc AM; Taylor MD; Foreman NK; Reigan P; Vibhakar R
    Mol Cancer; 2014 Mar; 13():72. PubMed ID: 24661910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
    Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD
    Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor.
    Mizuarai S; Yamanaka K; Itadani H; Arai T; Nishibata T; Hirai H; Kotani H
    Mol Cancer; 2009 Jun; 8():34. PubMed ID: 19500427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells.
    Toledo CM; Ding Y; Hoellerbauer P; Davis RJ; Basom R; Girard EJ; Lee E; Corrin P; Hart T; Bolouri H; Davison J; Zhang Q; Hardcastle J; Aronow BJ; Plaisier CL; Baliga NS; Moffat J; Lin Q; Li XN; Nam DH; Lee J; Pollard SM; Zhu J; Delrow JJ; Clurman BE; Olson JM; Paddison PJ
    Cell Rep; 2015 Dec; 13(11):2425-2439. PubMed ID: 26673326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic inhibition of the atypical kinase Wee1 selectively drives apoptosis of p53 inactive tumor cells.
    Pappano WN; Zhang Q; Tucker LA; Tse C; Wang J
    BMC Cancer; 2014 Jun; 14():430. PubMed ID: 24927813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells.
    Mak JP; Man WY; Chow JP; Ma HT; Poon RY
    Oncotarget; 2015 Aug; 6(25):21074-84. PubMed ID: 26025928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line.
    Hashimoto O; Shinkawa M; Torimura T; Nakamura T; Selvendiran K; Sakamoto M; Koga H; Ueno T; Sata M
    BMC Cancer; 2006 Dec; 6():292. PubMed ID: 17177986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role for Wee1 in inhibition of G2-to-M transition through the cooperation of distinct human papillomavirus type 1 E4 proteins.
    Knight GL; Turnell AS; Roberts S
    J Virol; 2006 Aug; 80(15):7416-26. PubMed ID: 16840322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.
    Wang Y; Li J; Booher RN; Kraker A; Lawrence T; Leopold WR; Sun Y
    Cancer Res; 2001 Nov; 61(22):8211-7. PubMed ID: 11719452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Murine Wee1 plays a critical role in cell cycle regulation and pre-implantation stages of embryonic development.
    Tominaga Y; Li C; Wang RH; Deng CX
    Int J Biol Sci; 2006; 2(4):161-70. PubMed ID: 16810330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Wee1-like protein kinase to treat cancer.
    Stathis A; Oza A
    Drug News Perspect; 2010 Sep; 23(7):425-9. PubMed ID: 20862394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells.
    Hirose Y; Berger MS; Pieper RO
    Cancer Res; 2001 Aug; 61(15):5843-9. PubMed ID: 11479224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells.
    Kreahling JM; Gemmer JY; Reed D; Letson D; Bui M; Altiok S
    Mol Cancer Ther; 2012 Jan; 11(1):174-82. PubMed ID: 22084170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.
    Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S
    Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma.
    Wu S; Wang S; Gao F; Li L; Zheng S; Yung WKA; Koul D
    Neuro Oncol; 2018 Jan; 20(1):78-91. PubMed ID: 29016926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.